Galecto (GLTO) News Today → Could this Tiny Biotech End Disease Forever? (From Behind the Markets) (Ad) Free GLTO Stock Alerts $0.70 -0.01 (-1.40%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineGLTO Stock Earnings: Galecto Beats EPS for Q1 2024investorplace.com - May 3 at 12:07 PMGalecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumabglobenewswire.com - May 1 at 4:01 PM6 Stocks Positioned to Soar as Investors Focus on MASHtheglobeandmail.com - April 22 at 9:59 AMGLTO Stock Earnings: Galecto Beats EPS for Q4 2023msn.com - March 15 at 2:17 PMGalecto Inc.thestreet.com - February 16 at 8:53 AMGalecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?finance.yahoo.com - February 14 at 2:55 PMWhat Makes Galecto, Inc. (GLTO) a New Strong Buy Stockfinance.yahoo.com - January 9 at 9:01 PMGalecto, Inc.: Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosisfinanznachrichten.de - December 23 at 1:23 AMNike, AAR And 3 Stocks To Watch Heading Into Fridaymsn.com - December 22 at 8:44 AMTopline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosisfinance.yahoo.com - December 21 at 7:15 PMGalecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trialfinance.yahoo.com - October 23 at 8:53 AMGalecto (GLTO) Price Target Increased by 13.16% to 5.48msn.com - October 5 at 8:57 AMGalecto, Inc.: Galecto Announces Plans to Explore Strategic Alternativesfinanznachrichten.de - October 2 at 12:26 AMHC Wainwright & Co. Downgrades Galecto (GLTO)msn.com - September 30 at 12:29 AMWeeks after dropping lung disease drug, Galecto lays off most of staff, explores salebizjournals.com - September 27 at 1:05 PMGalecto Announces Plans to Explore Strategic Alternativesfinance.yahoo.com - September 26 at 8:05 PMGalecto Biotech Collapse: Opportunity For Galectin Therapeuticsmsn.com - September 14 at 1:10 PMGalecto to Present at Investor Conferences in Septemberfinance.yahoo.com - August 31 at 8:02 PMHC Wainwright & Co. Maintains Galecto (GLTO) Buy Recommendationmsn.com - August 22 at 3:17 AMExpert Ratings for Galectomarkets.businessinsider.com - August 21 at 5:16 PMBiotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & Morefinance.yahoo.com - August 17 at 11:56 AMGalecto Ends Development of Lead Candidate After IPF Study Failure >GLTOmarketwatch.com - August 16 at 3:12 PMGalecto (GLTO) Down 71% as Lung Disease Candidate Failsfinance.yahoo.com - August 16 at 3:12 PMSVB Leerink Downgrades Galecto (GLTO)msn.com - August 15 at 8:43 PMGalecto shares plummet after biotech drops lung disease drugbizjournals.com - August 15 at 3:43 PMWhy Is Galecto Stock Plummeting Today?msn.com - August 15 at 3:43 PMGalecto to drop lung disease drug after Phase 2 setbackseekingalpha.com - August 15 at 10:43 AMGalecto to discontinue development of lung disease treatmentreuters.com - August 15 at 10:43 AMGalecto: Phase 2b Trial Of GB0139 In Idiopathic Pulmonary Fibrosis Fail To Meet Main Goal;stock Downmarkets.businessinsider.com - August 15 at 10:43 AMGalecto shares drop 65% as biotech halts development of lung-disease treatmentmsn.com - August 15 at 10:43 AMGalecto Shares Sink to New Lows After Lead Drug Candidate Scrapped >GLTOmarketwatch.com - August 15 at 10:43 AMGalecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosisfinance.yahoo.com - August 15 at 10:43 AMmarketbeat.com - August 15 at 9:36 AMmarketbeat.com - August 15 at 7:27 AMGalecto 10% Owner Sold $628K In Company Stockbenzinga.com - August 3 at 3:40 PMGalecto, Inc.: Galecto Reports Second Quarter Operating and Financial Resultsfinanznachrichten.de - August 1 at 7:42 PMGalecto (GLTO) Receives a Buy from H.C. Wainwrightmarkets.businessinsider.com - August 1 at 7:42 PMOppenheimer Reiterates Galecto (GLTO) Outperform Recommendationmsn.com - August 1 at 7:42 PMORBIMED ADVISORS LLC Reduces Stake in Galecto Incfinance.yahoo.com - July 28 at 12:00 PM10% Owner At This Health Care Company Sells $114K of Stockbenzinga.com - July 28 at 12:00 PMOrbimed Advisors Now Owns 9.6% of Galecto247wallst.com - July 19 at 12:29 AMGalecto Recent Insider Activitybenzinga.com - July 18 at 2:28 PMGalecto Inc Ordinary Sharesmorningstar.com - July 8 at 1:31 AMGalecto (GLTO) Price Target Increased by 9.09% to 12.24msn.com - July 6 at 11:02 PMOppenheimer Initiates Coverage of Galecto (GLTO) with Outperform Recommendationmsn.com - June 20 at 6:13 PMGalecto to join Russell Microcap Indexseekingalpha.com - June 20 at 1:12 PMGalecto an outperform at Oppenheimer on fibrosis assets catalystsmsn.com - June 20 at 1:12 PMGalecto Set to Join Russell Microcap® Indexfinance.yahoo.com - June 20 at 1:12 PMGalecto (GLTO) Initiated with a Buy at Oppenheimermarkets.businessinsider.com - June 20 at 8:11 AMGalecto to Present at the Upcoming Jefferies Healthcare Conferencefinance.yahoo.com - May 30 at 8:13 AM Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Could this Tiny Biotech End Disease Forever? (Ad)Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health. Access my full "Cut & Paste" profit analysis now. GLTO Media Mentions By Week GLTO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLTO News Sentiment▼1.220.37▲Average Medical News Sentiment GLTO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLTO Articles This Week▼21▲GLTO Articles Average Week Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aptorum Group News Today Indaptus Therapeutics News Today NeuroSense Therapeutics News Today KALA BIO News Today BioVie News Today Vincerx Pharma News Today Avalo Therapeutics News Today Sol-Gel Technologies News Today Talphera News Today Orgenesis News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLTO) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
